A multi-institutional, retrospective analysis of efficacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of acute phase Peyronie's Disease
Latest Information Update: 14 Aug 2020
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Peyronie's disease
- Focus Adverse reactions; Therapeutic Use
- 14 Aug 2020 New trial record
- 07 Aug 2020 Primary endpoint (The primary outcome of interest was the change in penile curvature with CCH therapy) has not been met.
- 07 Aug 2020 Results published in the Urology